New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2012
06:34 EDTSHLD, ONTYStocks with implied volatility movement; SHLD ONTY
Stocks with implied volatility movement; Sears Holdings (SHLD), Oncothyreon (ONTY) according to iVolatility.
News For SHLD;ONTY From The Last 14 Days
Check below for free stories on SHLD;ONTY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
10:15 EDTSHLDSears tumbles to fresh 52-week low, levels to watch
The shares hit a fresh 52-week low at $30.88 before bouncing slightly higher. WIth price last at $31.18, support is at that new low. A break below $30.88 would see next support at $30.10. Resistance is at $31.71, a pivot low on a closing basis, and then at $32.62.
06:35 EDTSHLDSears borrows $400M from CEO's hedge fund
Subscribe for More Information
September 12, 2014
09:14 EDTONTYOn The Fly: Pre-market Movers
Subscribe for More Information
08:39 EDTONTYOncothyreon says Merck KGaA discontinues development of tecemotide in NSCLC
Oncothyreon (ONTY) disclosed earlier in a regulatory filing that Merck KGaA (MKGAY), which has world-wide rights for the development and commercialization of tecemotide under a license agreement with Oncothyreon, announced that its biopharmaceutical division will discontinue the clinical development program of the investigational MUC1 antigen-specific cancer immunotherapy as a monotherapy in Stage III non-small cell lung cancer, or NSCLC. The decision to discontinue the current clinical program in NSCLC, which includes the Phase III START2 and INSPIRE studies, follows recent results from a planned analysis of EMR 63325-009, a randomized, double-blind, placebo-controlled Phase I/II study in Japanese patients. Merck Serono has made the decision to discontinue all other Merck Serono-sponsored clinical trials with tecemotide in NSCLC worldwide. Those patients on active treatment with tecemotide can undergo an individual assessment by their treating physician and apply to receive further treatment outside of the studies. Merck Serono will continue to supply tecemotide for ongoing investigator-sponsored trials in other indications in accordance with their agreements with the sponsors of these studies. Shares of Oncothyreon are down 12% in pre-market trading following the news from its partner.
September 10, 2014
11:43 EDTSHLDLand's End soars after better than expected Q2 results
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use